Do you resume immunotherapy (such as nivolumab) for metastatic melanoma after therapy-induced grade 4 hyperglycemia that has resolved?  

The answer is probably yes depending on the circumstances.  If on a trial then no.  If SOC then could consider it and since the patient probably has the equivalent of type 1 diabetes requiring insulin supplementation then unlikely to hurt them more.  If the pancreas recovered then it ...